| Efficacy and safety of low dosage amantadine hydrochloride as prophylaxis for influenza A. | |
| | |
MedLine Citation:
|
PMID: 2712549 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The efficacy and safety of prophylactic low dose amantadine hydrochloride was assessed in two double-blind, placebo-controlled, randomized studies. In a study of 476 subjects aged 18 to 55 years, adverse reactions were not significantly different between the group receiving 100 mg/day amantadine and the placebo group but significantly greater in the group given 200 mg/day (P less than 0.009). The influenza attack rate in this study was too low to assess efficacy. In an experimental challenge study of influenza A/Beth/1/85 in 78 subjects of similar age the prophylactic administration of 50 mg, 100 mg or 200 mg/day doses of amantadine were more effective than placebo in preventing influenza illness (P less than 0.02, 66, 74 and 82% protection, respectively), and in suppressing viral replication (P = 0.02). There was no significant difference between amantadine groups in influenza illness or viral shedding. Compared with the placebo group the 100 and 200 mg amantadine groups showed a significant decrease in infection rate (100 mg: 40% protection: P = 0.012; 200 mg: 32% protection: P = 0.045) whereas the 50 mg group did not (20% protection: P = 0.187). These results suggest that 100 mg/day of amantadine will reduce toxicity but maintain the prophylactic efficacy seen with 200 mg/day. |
| | |
Authors:
|
P D Reuman; D I Bernstein; M C Keefer; E C Young; J R Sherwood; G M Schiff |
Related Documents
:
|
23274819 - Measurements of indoor radon concentration levels in dwellings in bethlehem, palestine. 22927649 - Determination of radon level and radon effective dose rate using ssntd in dwellings in ... 23127069 - A real-time in vivo dosimetric verification method for high-dose rate intracavitary bra... 18949779 - Comparison of outcome measures from a trial of mycophenolate mofetil in myasthenia gravis. 15990219 - Treatment of overactive bladder in the older patient: pooled analysis of three phase ii... 23520199 - Estimation of organ and effective doses from newborn radiography of the chest and abdomen. 2412049 - Platelet hypersensitivity to serotonin after prolonged ketanserin intake? 20733579 - Phase i trial of cyt997, a novel cytotoxic and vascular-disrupting agent. 10638559 - Twenty-four-hour intragastric ph: tolerance within 5 days of continuous ranitidine admi... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Antiviral research Volume: 11 ISSN: 0166-3542 ISO Abbreviation: Antiviral Res. Publication Date: 1989 Feb |
Date Detail:
|
Created Date: 1989-06-07 Completed Date: 1989-06-07 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8109699 Medline TA: Antiviral Res Country: NETHERLANDS |
Other Details:
|
Languages: eng Pagination: 27-40 Citation Subset: IM |
Affiliation:
|
James N. Gamble Institute of Medical Research, Cincinnati, Ohio 45219. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Amantadine / adverse effects, therapeutic use* Dose-Response Relationship, Drug Double-Blind Method Humans Influenza A virus / drug effects, isolation & purification Influenza, Human / prevention & control* Middle Aged Placebos Random Allocation Time Factors Virus Replication / drug effects |
| Chemical | |
Reg. No./Substance:
|
0/Placebos; 768-94-5/Amantadine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Sucralfate reduces the gastrointestinal absorption of norfloxacin.
Next Document: Antiviral activity of tiazofurine against barley stripe mosaic virus.